Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
florbetaben (18F)
- Development stage
- Approved
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Neuraceq (florbetaben (18F)) is a fluorine-18 labeled diagnostic radiopharmaceutical developed by Life Molecular Imaging (acquired by Lantheus). It is a stilbene derivative that selectively binds to beta-amyloid neuritic plaques in the brain. Neuraceq is FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid plaque density in adult patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline. Additionally, florbetaben (18F) is under Phase 3 clinical development (including the CArdiag and CAPRI trials) for the non-invasive detection and characterization of cardiac and extracardiac amyloid deposits in patients with light-chain (AL) and transthyretin (ATTR) cardiac amyloidosis, for which it has received FDA Fast Track and Orphan Drug designations.
- Brand names
- Neuraceq
- Other names
- [18F]-florbetaben[18F]florbetabenflorbetabenflorbetaben F 18florbetaben F-18florbetaben F18fluorine-18-florbetabenfluorine18-florbetabenfluorine 18-florbetaben
02
Targets
SNCA (Alpha-synuclein)MAPT (Microtubule-associated protein tau)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on florbetaben (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on florbetaben (18F).